The Goldman Sachs Group Upgrades Autolus Therapeutics (NASDAQ:AUTL) to Buy

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by analysts at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research report issued on Monday, Marketbeat reports. The brokerage currently has a $7.60 price objective on the stock, up from their prior price objective of $7.00. The Goldman Sachs Group’s target price would indicate a potential upside of 157.63% from the stock’s previous close.

Several other analysts have also recently issued reports on AUTL. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics has an average rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock opened at $2.95 on Monday. The stock has a market capitalization of $784.97 million, a price-to-earnings ratio of -2.44 and a beta of 2.04. The company has a fifty day moving average of $3.86 and a 200-day moving average of $3.97. Autolus Therapeutics has a 52-week low of $2.88 and a 52-week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the company earned ($0.26) earnings per share. On average, equities research analysts forecast that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AUTL. Wellington Management Group LLP lifted its position in Autolus Therapeutics by 35.4% during the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after acquiring an additional 6,330,392 shares during the period. State Street Corp grew its position in Autolus Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after purchasing an additional 10,401 shares during the last quarter. HighVista Strategies LLC increased its stake in Autolus Therapeutics by 2.7% during the 3rd quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after purchasing an additional 14,204 shares in the last quarter. Erste Asset Management GmbH purchased a new position in Autolus Therapeutics in the third quarter worth about $708,000. Finally, Bellevue Group AG increased its holdings in shares of Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.